A Study to Evaluate Cancer Patients' Experience with Bevacizumab- induced, Wound-healing Complications


About this study

The purpose of this study is to characterize the experiences and psychosocial impact of bevacizumab-wound-healing toxicities in cancer patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Cancer patients who have received bevacizumab and have developed a skin-related complication as described above.
  • An adult caregiver who provides care to the patient and has been nominated for study participation.
  • Patients who are unable to nominate a caregiver will still be eligible to participate in the study.

Exclusion Criteria: 

  • Adult below the age of 18 years.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Gladys Asiedu, Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer